Insulin like growth factor I (IGF-I) serum level modifications during transdermal estradiol treatment in postmenopausal women: A possible bimodal effect depending on basal IGF-I values

Gynecological Endocrinology

Volumn 12, Issue 4, 1998, Pages 259-266

  Campagnoli, C ^a,c   Biglia, N ^b   Cantamessa, C ^a   Lesca, L ^a   Lotano, M R ^a   Sismondi, P ^b  

^a St Anna Gynecologic Hospital

^b UNIVERSITY OF TURIN   (Italy)

^c NONE   (Italy)

Author keywords

Estrogen replacement therapy; Growth hormone; Insulin like growth factor I; Sex hormone binding globulin; Somatomedin C; Transdermal estradiol

Indexed keywords

DYDROGESTERONE; ESTRADIOL; GROWTH HORMONE; SEX HORMONE BINDING GLOBULIN; SOMATOMEDIN C;

ADRENERGIC SYSTEM; ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET RESTRICTION; FEMALE; HORMONE BLOOD LEVEL; HUMAN; LIVER; MAJOR CLINICAL STUDY; MENOPAUSE; POSTMENOPAUSE; PRIORITY JOURNAL; TRANSDERMAL DRUG ADMINISTRATION;

EID: 0031689861     PISSN: 09513590     EISSN: None     Source Type: Journal    
DOI: 10.3109/09513599809015598     Document Type: Article

References (26)

1. Iranmanesh A, Veldhuis JD. Clinical pathophysiology of the somatotropic (GH) axis in adults. Endocrinol Metab Clin N Am 1992;21:783-816
2. Westley DR, May FEB. Role of insulin-like growth factors in steroid modulated proliferation. J Steroid Biochem Mol Biol 1994;51:1-9
3. Ho KKY, O'Sullivan AJ, Weissberger AJ, et al. Sex steroid regulation of growth hormone secretion and action. Horm Res 1996;45:67-73
4. Ravn P, Overgaard K, Spencer EM, et al. Insulin-like growth factors I and II in healthy women with and without established osteoporosis. Eur J Endocrinol 1995;132:313-19
5. Weissberger AJ, Ho KKY, Lazarus L. Contrasting effects of oral and transdermal routes of estrogen replacement therapy on 24-hour growth hormone (GH) secretion, insulin-like growth factor I, and GH-binding protein in postmenopausal women. J Clin Endocrinol Metab 1991;72:374-81
6. Bellantoni MF, Harman SM, Cho DE, et al. Effects of progestin-opposed transdermal estrogen administration on growth hormone and insulin-like growth factor I in postmenopausal women of different ages. J Clin Endocrinol Metab 1991;72:172-8
7. Slowinska-Srzednicka J, Zgliczynski S, Jeske W, et al. Transdermal 17β-estradiol combined with oral progestogen increases plasma levels of insulin-like growth factor-I in postmenopausal women. J Endocrinol Invest 1992;15:533-8
8. Campagnoli C, Biglia N, Altare F, et al. Differential effects of oral conjugated estrogens and transdermal estradiol on insulin-like growth factor I, growth hormone and sex hormone binding globulin serum levels. Gynecol Endocrinol 1993;7:251-8
9. De Leo V, Lanzetta D, D'Antona D, et al. Growth hormone secretion in premenopausal women before and after ovariectomy: effect of hormone replacement therapy. Fertil Steril 1993;60:268-71
10. Mercuri N, Petraglia F, Genazzani AD, et al. Hormonal treatments modulate pulsatile plasma growth hormone, gonadotropin and osteocalcin levels in postmenopausal women. Maturitas 1993;17:51-62
11. Liberman SA, Mitchell AM, Marcus R, et al. The insulin-like growth factor I generation test: resistance to growth hormone with aging and estrogen replacement therapy. Horm Metab Res 1994;26:229-33
12. Dall'Aglio E, Valenti G, Hoffman AR, et al. Lack of effect of transdermal estrogen on the growth hormone-insulin-like growth factor axis. Horm Metab Res 1994;26:211-12
13. Hartmann B, Kirchengast S, Albrecht A, et al. Effects of hormone replacement therapy on growth hormone secretion patterns in correlation to somatometric parameters in healthy postmenopausal women. Maturitas 1995;22:239-46
14. Friend KE, Hartman ML, Pezzoli SS, et al. Both oral and transdermal estrogen increase growth hormone release in postmenopausal women. A clinical research center study. J Clin Endocrinol Metab 1996; 81:2250-6
15. Bellantoni MF, Vittone J, Campfield AT, et al. Effects of oral versus transdermal estrogen on the growth hormone/insulin-like growth factor I axis in younger and older postmenopausal women: a clinical research center study. J Clin Endocrinol Metab 1996;81:2848-53
16. Carmina E, Lo Dico G, Carollo F, et al. Serum IGF-I and binding proteins 1 and 3 in postmenopausal women and the effects of estrogen. Menopause J North Am Menop Soc 1996;3:85-9
17. Helle SI, Omsjo IH, Cwyfan Hughes SC, et al. Effects of oral and transdermal oestrogen replacement therapy on plasma levels of insulin-like growth factors and IGF binding proteins 1 and 3: a cross-over study. Clin Endocrinol 1996;45:727-32
18. Goodman-Gruen D, Barrett-Connor E. Effect of replacement estrogen on insulin-like growth factor-I in postmenopausal women: The Rancho Bernardo Study. J Clin Endocrinol Metab 1996;81:4268-71
19. Kazer RR. Breast cancer and the reproductive endocrinologist. Fertil Steril 1996;65:470-1
20. Campagnoli C, Biglia N, Lanza MG, et al. Androgenic progestogens oppose the decrease of insulin-like growth factor I serum level induced by conjugated oestrogens in postmenopausal women. Preliminary report. Maturitas 1994;19:25-31
21. Campbell S, Whitehead MI. Potency and hepatocellular effects of oestrogens after oral, percutaneous, and subcutaneous administration. In van Keep PA, Utian WH, Vermeulen A, eds. The Controversial Climacteric. Lancaster, UK: MTP Press, 1982:103-25
22. Holly JMP. The physiological role of IGFBP-1. Acta Endocrinol (Copenh) 1991;124:55-62
23. Gaspard UJ, Gottal J-M, van den Brûle FA. Postmenopausal changes of lipid and glucose metabolism: a review of their main aspects. Maturitas 1995;21:171-8
24. Clemmons DR, Underwood LE, Ridgeway EG, et al. Estradiol treatment of acromegaly: reduction of immunoreactive somatomedin C and improvement in metabolic status. Am J Med 1980;69:571-5
25. Kazer RR. Insulin resistance, insulin-like growth factor I and breast cancer: a hypothesis. Int J Cancer 1995;62:403-6
26. Campagnoli C, Biglia N, Peris C, et al. Potential impact on breast cancer risk of circulating insulin-like growth factor I modifications induced by oral HRT in menopause. Gynecol Endocrinol 1995;9:67-74